EDSA
What one share of Edesa Biotech holds
Pharmaceutical Preparations
We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our approach is to acquire, develop and commercialize drug candidates based on mechanisms of action that have demonstrated proof-of-concept in human subjects.
Edesa Biotech’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.73 |
|---|---|
| Cash and investments | $1.07 |
| Book value | $0.91 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.01 | −$3.99 | $0.32 | −$3.89 | — | $8.50 |
| 2017 | $0.16 | −$3.44 | $0.21 | −$3.42 | — | $4.92 |
| 2018 | $0.07 | −$1.76 | $0.13 | −$1.74 | — | $0.67 |
| 2018 | $0.00 | −$0.47 | $0.00 | −$0.40 | — | $0.99 |
| 2020 | $0.04 | −$0.74 | $0.00 | −$0.58 | — | $0.69 |
| 2021 | $0.00 | −$1.10 | $0.00 | −$1.13 | — | $0.98 |
| 2023 | — | −$2.93 | $0.00 | −$2.32 | — | $2.29 |
| 2024 | — | −$1.93 | — | −$1.53 | — | $0.61 |
| 2025 | — | −$1.27 | — | −$1.29 | — | $1.74 |